Profile data is unavailable for this security.
About the company
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.
- Revenue in CNY (TTM)191.78m
- Net income in CNY-27.11m
- Incorporated2012
- Employees401.00
- LocationShanghai Rightongene Biotechnology Co Ltd#6055 Jinhai ExpresswayFengxian District, Building 3Shanghai 201403ChinaCHN
- Phone+86 2 133282601
- Fax+86 2 137199015
- Websitehttps://www.rightongene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Rightongene Biotechnlgy Co Ltd | 191.78m | -27.11m | 1.74bn | 401.00 | -- | 1.92 | -- | 9.06 | -0.4824 | -0.4824 | 3.42 | 16.18 | 0.1954 | 1.29 | 1.14 | 478,253.60 | -4.05 | 2.48 | -4.25 | 2.67 | 70.61 | 69.35 | -20.73 | 7.60 | 13.93 | -- | 0.0028 | 16.94 | -6.16 | -1.05 | -298.78 | -- | -6.04 | -- |
| Jiangsu Nanfang Medical Co Ltd | 594.86m | -202.28m | 1.93bn | 850.00 | -- | 7.59 | -- | 3.25 | -0.6998 | -0.6998 | 2.06 | 0.88 | 0.5305 | 2.60 | 4.50 | 699,834.10 | -18.06 | -4.62 | -51.29 | -9.50 | -5.00 | 15.52 | -34.03 | -8.29 | 0.2557 | -6.48 | 0.6396 | -- | 0.4199 | 4.15 | -29.34 | -- | -10.48 | -- |
| AVE Science & Technology Co Ltd | 221.12m | 26.95m | 1.93bn | 503.00 | 71.66 | 3.73 | -- | 8.73 | 0.3963 | 0.3963 | 3.25 | 7.62 | 0.3796 | 2.09 | 40.74 | 439,603.90 | 4.63 | 5.20 | 5.19 | 5.87 | 55.98 | 57.49 | 12.19 | 12.48 | 4.47 | -- | 0.0547 | 32.92 | 1.50 | 1.37 | 6.07 | -14.68 | -31.29 | -- |
| Suzhou Iron Technology Co Ltd | 381.50m | 5.23m | 2.11bn | 680.00 | 346.59 | 2.72 | -- | 5.54 | 0.079 | 0.079 | 5.10 | 10.06 | 0.2822 | 2.23 | 1.50 | -- | 0.4366 | 4.75 | 0.7154 | 7.34 | 43.10 | 53.91 | 1.55 | 14.71 | 1.20 | 1.29 | 0.2133 | 31.78 | -10.52 | 2.22 | -173.52 | -- | -- | -- |
| Shanghai Rendu Biotechnology Co Ltd | 165.86m | -5.47m | 2.14bn | 335.00 | -- | 2.33 | -- | 12.92 | -0.1374 | -0.1374 | 4.14 | 22.92 | 0.1662 | 1.62 | 2.93 | 495,112.60 | -0.5482 | 4.37 | -0.5875 | 4.91 | 76.46 | 73.71 | -3.30 | 12.61 | 13.50 | -- | 0.0047 | 11.16 | 7.87 | 12.33 | -194.59 | -- | -28.11 | -- |
| Guangzhou LBP Medicine Scnc&Tech Co Ltd | 371.03m | -19.11m | 2.59bn | 796.00 | -- | 2.11 | -- | 6.98 | -0.2042 | -0.2042 | 3.97 | 13.10 | 0.2761 | 1.55 | 1.71 | 466,121.80 | -1.49 | 3.50 | -1.55 | 3.78 | 63.03 | 72.02 | -5.41 | 9.79 | 7.80 | -- | 0.0118 | 32.69 | -5.33 | 5.80 | -46.85 | -22.05 | -7.83 | -- |
Data as of Feb 13 2026. Currency figures normalised to Shanghai Rightongene Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 725.98k | 1.98% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2025 | 166.08k | 0.45% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 77.48k | 0.21% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2025 | 75.02k | 0.20% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 51.96k | 0.14% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2025 | 23.40k | 0.06% |
| Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 2025 | 18.54k | 0.05% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 17.33k | 0.05% |
| Lion Fund Management Co., Ltd.as of 30 Jun 2025 | 17.00k | 0.05% |
| AVIC Fund Management Co. Ltd.as of 30 Jun 2025 | 14.14k | 0.04% |
More ▼
Data from 30 Jun 2025 - 30 Nov 2025Source: FactSet Research Systems Inc.
